With the Union’s budget on the corner vault, Biocon’s executive chairman Kiran Mazumdar-Shaw stated his anticipation on Saturday, frameing his expectations with a clear call for investment based on research. “Attentively waiting for FM Sitharaman’s budget address. Incentives linked to research expect to mention a mention. We need budget allocation for mission mission mission, quantum cell, gene therapy, synthetic biology and smart medtech “, Mazumdar-Shaw wrote, emphasizing the sectors that believe that they are critical of the next wave of growth in India.

His statements occur when the Minister of Finance, Nirmala Sitharaman, presented his eighth consecutive budget. This budget involves an increase in expectations in the midst of economic heads marked by high prices and stagnant salary growth, which especially affects the middle class. A potential adjustment in income or slabs tax types is widely foreseen, intended to relieve the financial tension of homes.

Analysts predict that the budget will achieve a balance between increasing consumption and maintaining tax discipline. Although there is a strong hope of relief measures aimed at the lower middle class, especially after the recent comments of Prime Minister Narendra Modi invoking the goddess of wealth to raise the poor, he also focuses on structural reforms. Experts provide for fiscal rationalization, export promotion and better implementation of capital spending plans as key pillars of the budget.

Mazumdar-Shaw’s emphasis on mission assignments for sectors such as artificial intelligence, quantum technologies, gene therapy and synthetic biology aligns with the widest industry expectations to improve research. and development support. The Government is also expected to expand production -related incentives, increase the assignments for well -being schemes and continue infrastructure updates.

As fiscal consolidation is still a priority, with a 4.5% of GDP for FY26, the budget will probably walk through growth, stimulating growth by maintaining intact fiscal caution. Whether Mazumdar-Shaw’s hopes to materialize incentives linked to research will be closely monitored by the scientific and business communities.